Introduction
============

Cancer is a leading cause of death worldwide and the total number of cases globally is increasing. The number of cancer deaths is projected to increase 45% from 2007 to 2030 (from 7.9 million to 11.5 million deaths), influenced in part by an increasing and aging global population. The estimated rise takes into account expected slight declines in death rates for some cancers in high resource countries. New cases of cancer in the same period are estimated to increase from 11.3 million in 2007 to 15.5 million in 2030 (WHO, [@B79]). In Chile cancer have a rate of 133.7 × 100,000 inhabitants, is the second cause of death after cardiovascular diseases with a sustained increase in the time both, in the rates and in proportion of deaths. Chile has a number of 30,000 new cases and 36,000 hospitalizations per year. The first cause of cancer death in Chilean population is gastric cancer for both genders, with a rate of 19.8 × 100,000 inhabitants, followed by lung cancer (15 × 100,000 inhabitants), prostate (10.4 × 100,000 inhabitants), and gallbladder (8.1 × 100,000 inhabitants; DEIS, [@B22]).

Though the principal achievements in the fight against cancer has been those related to preventive measures, the success in the treatment of an established cancer depends on the cancer stage when detected, on the type of cancer, and on its location. It is quite infrequent to find patients considered as "therapeutical success" because there is always a possibility that a tumor process may appear back (Arrastoa, [@B7]).

Chemotherapy for cancers has progressed from its introduction to clinical practice and constitutes the mainstay modality of therapy in these pathologies. Nevertheless, its use is limited by the inability to predict the response. In most cases the therapy choice is empirical. Nowadays there are more than 100 antineoplastic drugs, which are used either alone or combined. A combined therapy allows that drugs with different mechanism of action work together to destroy the larger possible amount of tumor cells, in order to reduce the possibility of resistance to a particular antineoplastic drug. The therapy to select, the dose, the method of administration and the frequency, and duration of the treatment, will depend on the type of cancer, its location, the rate of growth, how it is affecting the normal functions of the body, as well as on the patient's general health condition. Usually therapies can be managed by means of cycles that alternate drug administration with washout periods that allow healthy cells to recover from the effect of the medication.

The biotransformation of drugs, including antineoplastic agents, is done basically in two phases: phase I, catalyzed mainly by the cytochrome P450 system and phase II, by transferases that catalyze reactions of conjugation of xenobiotics with diverse molecules of endogenous nature as glucuronic acid, sulfates, acetate, glutathione, or some amino acids. The final outcome of both phases is to increase the hydrophilicity of chemicals facilitating the excretion through urine or bile (Rooney et al., [@B67]).

There is limited information available in human beings regarding the metabolism and pharmacokinetics interaction of antineoplastic drugs. Nevertheless, it is well known that clinical significant interactions exist between drugs that can render them less efficient if used simultaneously, and in some cases, produce unexpected effects.

The cytochrome P450 (CYP) system is the most important metabolic system responsible for the oxidation of numerous chemotherapeutic agents, and it is responsible to a great extent for the variability observed in response to drugs. For example, some enzymes of the CYP3A family play an important role in the metabolism of epidophilotoxin, ifosfamide, tamoxifen, taxol, and vinca alkaloids. Cytochrome P450 enzymes are also of great importance in the study of chemotherapy resistance. (Kivisto et al., [@B41]; Yao et al., [@B82]; Lin and Yu, [@B48]; García-Martín et al., [@B27]; Quiñones et al., [@B62]).

Genetic polymorphisms of CYP enzymes can produce deep changes in enzyme activity, thus determining the individual response to a certain drug leading to poor, intermediate, extensive, or ultrarapid metabolizer phenotypes (Ingelman-Sundber, [@B36]; Jin, [@B38]). On the other hand, the glucuronidation of drugs is carried out by the UDP Glucuronyl transferases (UGT), which are also polymorphic in human beings, adding to the diversity of this reaction. In this respect, UGT2B7 has unique specificity for 3,4-catechol estrogens and estriol, suggesting that it may play an important role in regulating the level and activity of these potent estrogen metabolites. It is also able to conjugate major classes of drugs such as analgesics (morphine), carboxylic non-steroidal anti-inflammatory drugs (ketoprofen), anticarcinogens (all-trans retinoic acid), and tamoxifen. 802C/T mutation leads to UGT2B7 variants UGT2B7\*1 (Y268) and UGT2B7\*2 (H268) which has been suggested to increase the activity of the enzyme (Ritter et al., [@B65]; Coffman et al., [@B20]; Barre et al., [@B9]; Lazarus et al., [@B44]). Similarly, the human glutathione-*S*-transferases (GSTs), are polymorphic isoenzymes which show a wide subcellular distribution. GST alpha (α), kappa (κ), mu (μ), pi (π), omega (ω), sigma (σ), theta (θ), and zeta (Z are being studied as possible genetic biomarkers of cancer and its chemotherapeutic treatment (Guengerich et al., [@B32]; Quiñones et al., [@B60]; Bredschneider et al., [@B11]). These enzymes are fundamental in the oxidative processes and detoxification of a wide variety of xenobiotics, including many chemotherapeutic drugs (Massad-Massade et al., [@B51]; Sargent et al., [@B71]; Clapper, [@B19]; Bredschneider et al., [@B11]; Petros et al., [@B59]). These polymorphisms have been postulated also as biomarkers for susceptibility to diverse types of cancer (IARC, [@B35]; Clapper, [@B19]; Au, [@B8]; Quiñones et al., [@B61]; Acevedo et al., [@B1]; Keshava et al., [@B39]; Lee et al., [@B45]; Cordero et al., [@B21]; Singh et al., [@B73]) showing marked interethnic differences (Stephens et al., [@B75]; Muñoz et al., [@B53]; Garte et al., [@B29]; Yasuda et al., [@B83]).

Another relevant enzyme is methylene tetrahydrofolate reductase (MTHFR) which converts 5,10-methylene tetrahydrofolate to 5-methyl tetrahydrofolate. This reaction is required for the multistep process that converts the amino acid homocysteine to another amino acid, methionine. Polymorphisms of this enzyme predispose to serious bone marrow toxicity during treatment with agents that inhibit folate synthesis (e.g., methotrexate; Chiuslo et al., [@B18]; Yang et al., [@B81]).

Because of enzymes CYP1A1, CYP1A2, CYP2A6, CYP3A4/5, CYP2C8, CYP2C9, CYP2C19, CYP2E1, CYP2D6, GSTM1, GSTT1, UGT2B7, and MTHFR take part in the metabolism of oncological drugs (Table [1](#T1){ref-type="table"}), the main goal of this study was to determine the allele frequencies of variants of these enzymes in a group representative of the Chilean population in order to describe genetic polymorphisms that might be useful in public health programs, and to compare these frequencies with other populations, as the first approximation to the evaluation of ethnic differences in the response to chemotherapies.

###### 

**General characteristics of the studied population**.

  Sex                                              Women         Men           Total
  ------------------------------------------------ ------------- ------------- -------------
  Number                                           155           98            253
  Age (years)[\*](#tfn1){ref-type="table-fn"}      33.6 ± 13.6   28.7 ± 10.8   31.7 ± 12.8
  Weight (kg)[\*](#tfn1){ref-type="table-fn"}      61.8 ± 9.1    74.9 ± 10.1   66.8 ± 11.4
  Height (m)[\*](#tfn1){ref-type="table-fn"}       1.60 ± 0.06   1.73 ± 0.07   1.65 ± 0.09
  BMI (Kgm^−2^)[\*](#tfn1){ref-type="table-fn"}    24.1 ± 3.3    25.0 ± 2.9    24.5 ± 3.2
  A~A--C~: 37%[\*\*](#tfn2){ref-type="table-fn"}                               

\**Information is expressed as averages ± SD; BMI: body mass index*.

\*\**Amerindian-Caucasian Admixture (%)*.

Materials and Methods
=====================

Study population
----------------

Blood samples were obtained from 253 unrelated volunteers living in Santiago of Chile (both sexes, 27--55 years old). The study group has a 37% Amerindian-Caucasian admixture, as determined by ABO blood group distribution (Valenzuela, [@B77]). The research was authorized by the Ethics Committee of the Faculty of Medicine of the University of Chile. All subjects signed an authorized informed consent. Table [1](#T1){ref-type="table"} shows general characteristics of the studied population.

DNA extraction
--------------

Extraction of genomic DNA was done by a standard procedure from whole blood using a commercial kit (High Pure PCR Template Preparation Kit, Roche Diagnostics^®^) and DNA samples were stored at -20°C until further analysis.

Genotyping
----------

Genomic DNAs from peripheral blood were amplified by PCR using specific primers for detection of the specific allelic variants in study. For detection of polymorphisms *CYP1A1*\**2A*, *CYP1A1*\**2C*, *CYP1A2*\**1F*, *CYP2E1*\**5B*, *CYP2E1*\**6*, *CYP2A6*\**2*, *CYP2A6*\**3*, *CYP2A6*\**4*, *CYP2D6*\**2*, *CYP2C9*\**2*, *CYP2C19*\**2*, *CYP3A4*\**1B*, *CYP3A4*\**17*, *CYP3A5*\**3*, and *UGT2B7*\**2*, amplicons were surrendered to digestion with the appropriate restriction enzyme to be analyzed through electrophoresis, in agarose gel (2%) or polyacrylamide gel (16%) according to methods previously reported (Hayashi et al., [@B33]; Kitagawa et al., [@B40]; Quiñones et al., [@B60]; Cavalli et al., [@B14]; LEE et al., [@B46]; Lin et al., [@B47]). *CYP2D6*\**3* and *CYP2D6*\**4* were analyzed by means of allele-specific PCR (Heim and Meyer, [@B34]; Amrithraj et al., [@B6]). *CYP2C9*\**3*, *CYP2C19*\**3*, and *CYP2C8*\**3* polymorphisms were analyzed with *Taqman* probes in an ABI 7500 Real Time PCR system, using specific probes previously described (Agúndez et al., [@B3]). Deletions of *GSTM1* and *GSTT1* were analyzed through PCR using β-globin gene as control (Quiñones et al., [@B60]; Rebbeck et al., [@B63]). Heterozygous and homozygous non-null individuals could not be differentiated, therefore double null genotypes (−/−) are the null genotypes reported. Finally, to detect *MTHFR* C677T polymorphism we use a commercial Real Time kit (Roche Diagnostics^®^).

Results and Discussion
======================

Pharmacogenetic research is directed to identify genes or gene products associated with diseases and, especially, allelic variants in enzymes of biotransformation that alter the individual response to drugs. These variants can modify the magnitude of the pharmacological effect, the threshold of toxicity, the efficacy of the drug, side effects, and drug--drug interactions. In this respect, it is particularly important at the time, to define pharmacogenetic profiles of patients with cancer to determine suitable dosages, to improve efficacy, to avoid adverse reactions of the traditionally used drugs, and to develop new drugs according to the genetic -- metabolic profile of the patients (Wilkinson, [@B80]). Moreover, ethnicity plays an important role in pharmacokinetics and pharmacodynamics of drugs (Ling and Lee, [@B49]; Kurose et al., [@B43]) giving rise a more complex situation in "mestizo" populations as South American people. In this sense, Chilean population is a genetic admixture originated primarily between Caucasian (mainly Spaniards) and native-American (mainly Mapuches) from a first single migration of Asians from Siberia 15,000 years ago through Beringia (Reich et al., [@B64]) and secondly from immigration, mostly from Germany, Croatia, France and Italy. This is a restriction to extrapolate the dosage of drugs with clinical studies performed in other ethnic groups. Another restriction is the poor information about the biotransformation enzyme polymorphisms in Chilean population. According to this, we have studied genetic polymorphisms of several enzymes, in a sub-group of the Chilean population, which metabolize mainly antineoplastic drugs used for chemotherapy in health institutions of Chile (Table [1](#T1){ref-type="table"}). General characteristics of the analyzed population are shown in Table [2](#T2){ref-type="table"}. The mean age identifies a young adult population which has, in average, a normal mean weight, height, and body mass index and are a representative sample of the middle class Chilean population, which is supported by the Amerindian-Caucasian admixture (37%).

###### 

**Some antineoplastic drugs, substrates of polymorphic enzymes analyzed in this research (<http://www.pharmacologyweekly.com/content/pages/cytochrome-cyp-p450-enzyme-medication-herbs-substrates>; Quiñones et al., [@B62])**.

  Drugs                                      Enzyme                                            Cancer
  ------------------------------------------ ------------------------------------------------- --------------------------------------------
  Cisplatin                                  GSTM, GSTT                                        Breast
  Cyclophosphamide                           CYP2B6, CYP2C19, CYP3A4                           Leukemia, lymphoma
  Dacarbazine                                CYP1A1, CYP1A2, CYP2E1                            Melanoma, sarcoma, lymphoma
  Docetaxel                                  CYP2C8, CYP3A, CYP1B1                             Breast, lung, stomach
  Doxorubicin                                CYP3A4                                            Sarcoma
  Ellipticine                                CYP3A4, CYP1A                                     Leukemia, myeloma, lymphosarcoma
  Etoposide                                  CYP3A4, CYP2E1, CYP1A2                            Testicle, lung, breast, leukemia, lymphoma
  Ifosfamide                                 CYP2B6, CYP3A4                                    Sarcoma, testicle
  Imatinib                                   CYP3A4, CYP3A5                                    Leukemia
  Irinotecan                                 CYP3A4/5                                          Colon and rectum
                                             UGT1A1                                            
  Methotrexate                               MTHFR                                             Leukemia
  Mitoxantrone                               CYP3A4, CYP1B1                                    Leukemia, lymphoma
  Paclitaxel                                 CYP2C8, CYP3A4                                    Breast, lung, ovary
  Phortress (2-(4-aminophenyl-benzotiazol)   CYP1A1, CYP1B1                                    Ovary, breast
  Procarbazine                               CYP1A1, CYP2B6                                    Lymphoma, brain, lung, melanoma, testicle
  Tamoxifen                                  CYP3A4, CYP2D6, CYP2C9, CYP2C19, CYP1B1, UGT2B7   Breast
  Tegafur                                    CYP2A6, CYP2C8, CYP1A2                            Colon, rectum, stomach
  Teniposide                                 CYP2C19, CYP3A4/5                                 Leukemia, lung, brain, bladder, myeloma
  Thiotepa                                   CYP2B6, CYP3A4                                    Bladder
  Topotecan                                  CYP3A4/5                                          Ovary, lung
  Vinblastine                                CYP3A4/5                                          Lymphoma, osteosarcoma
  Vincristine                                CYP3A4/5                                          Lymphoma
  Vindesine                                  CYP3A4/5                                          Lung
  Vinrelbine                                 CYP3A4/5                                          Lung

The allele and genotype frequencies for metabolic enzymes included in this research are shown in the Table [3](#T3){ref-type="table"}. Due to DNA shortage, not all DNA samples were analyzed for all polymorphisms. In Table [4](#T4){ref-type="table"} we compare allele frequencies found in this study in relation to Caucasian and Asian populations.

###### 

**Genotype and allele frequencies of CYP1A1, CYP1A2, CYP2A6, CYP3A4/5, CYP2C8, CYP2C9, CYP2C19, CYP2E1, CYP2D6, UGT2B7, GSTM1, GSTT1 y MTHFR polymorphisms in a Chilean mestizo population**.

  CYP1A1\*2A      *n*       \%       CYP1A1\*2C          *n*       \%       CYP1A2\*1F       *n*       \%       CYP2A6\*2        *n*       \%       CYP2A6\*3        *n*       \%       CYP2A6\*4        *n*       \%
  --------------- --------- -------- ------------------- --------- -------- ---------------- --------- -------- ---------------- --------- -------- ---------------- --------- -------- ---------------- --------- --------
  \*1/\*1         112       44.27    \*1/\*1             79        43.89    \*1A/\*1A        18        7.11     \*1A/\*1A        244       100.00   \*1A/\*1A        253       100.00   \*1A/\*1A        244       100.00
  \*1/\*2A        95        37.55    \*1/\*2C            86        47.78    \*1A/\*1F        81        32.02    \*1A/\*2         9         0.00     \*1A/\*3         0         0.00     \*1A/\*4         0         0.00
  \*2A/\*2A       46        18.18    \*2C/\*2C           15        8.33     \*1F/\*1F        154       60.87    \*2/\*2          0         0.00     \*3/\*3          0         0.00     \*4/\*4          9         0.00
  TOTAL           253       100.0    TOTAL               180       100.00   TOTAL            253       100.00   TOTAL            253       100.00   TOTAL            253       100.00   TOTAL            253       100.00
  fwt             0.63               *f*\*1              0.68               *f*\*1A          0.23               *f*\*1A          0.98               *f*\*1A          1.00               *f*\*1A          0.96      
  *f*\*2A         0.37               *f*\*2C             0.32               *f*\*1F          0.77               *f*\*2           0.02               *f*\*3           0.00               *f*\*4           0.04      
                                                                                                                                                                                                                   
  **CYP2C8\*3**   ***n***   **%**    **CYP2C9\*2**       ***n***   **%**    **CYP2C9\*3**    ***n***   **%**    **CYP2C19\*2**   ***n***   **%**    **CYP2C19\*3**   ***n***   **%**    **CYP2D6\*2**    ***n***   **%**
                                                                                                                                                                                                                   
  \*1A/\*1A       157       87.22    \*1A/\*1A           225       88.93    \*1A/\*1A        167       92.78    \*1A/\*1A        201       79.45    \*1A/\*1A        253       100.00   \*1A/\*1A        88        34.78
  \*1A/\*3        23        12.78    \*1A/\*2            26        10.28    \*1A/\*3         13        7.22     \*1A/\*2         44        17.39    \*1A/\*3         0         0.00     \*1A/\*2         121       47.83
  \*3/\*3         0         0.00     \*2/\*2             2         0.79     \*3/\*3          0         0.00     \*2/\*2          8         3.16     \*3/\*3          0         0.00     \*2/\*2          44        17.39
  TOTAL           180       100.00   TOTAL               253       100.00   TOTAL            180       100.00   TOTAL            253       100.00   TOTAL            253       100.00   TOTAL            253       100.00
  *f*\*1A         0.94               *f*\*1A             0.94               *f*\*1A          0.96               *f*\*1A          0.88               *f*\*1A          1.00               *f*\*1A          0.59      
  *f*\*3          0.06               *f*\*2              0.06               *f*\*3           0.04               *f*\*2           0.12               *f*\*3           0.00               *f*\*2           0.41      
                                                                                                                                                                                                                   
  **CYP2D6\*3**   ***n***   **%**    **CYP2D6\*4**       ***n***   **%**    **CYP2E1\*5B**   ***n***   **%**    **CYP2E1\*6**    ***n***   **%**    **CYP3A4\*1B**   ***n***   **%**    **CYP3A4\*17**   ***n***   **%**
                                                                                                                                                                                                                   
  \*1A/\*1A       248       98.02    \*1A/\*1A           198       78.26    \*1A/\*1A        135       75.00    \*1A/\*1A        123       68.33    \*1A/\*1A        225       88.93    \*1A/\*1A        253       100.00
  1A/\*3          5         1.98     1A/\*4              50        19.76    \*1A/\*5B        39        21.67    \*1A/\*6         45        25.00    \*1A/\*1B        28        11.07    \*1A/\*17        0         0.00
  \*3/\*3         0         0.00     \*4/\*4             5         1.98     \*5B/\*5B        6         3.33     \*6/\*6          12        6.67     \*1B/\*1B        0         0.00     \*17/\*17        0         0.00
  TOTAL           253       100.00   TOTAL               253       100.00   TOTAL            180       100.00   TOTAL            180       100.00   TOTAL            253       100.00   TOTAL            253       100.00
  *f*\*1A         0.99               *f*\*1A             0.88               *f*\*1A          0.86               *f*\*1A          0.81               *f*\*1A          0.95               *f*\*1A          1.00      
  *f*\*3          0.01               *f*\*4              0.12               *f*\*5B          0.14               *f*\*6           0.19               *f* \*1B         0.06               *f*\*17          0.00      
                                                                                                                                                                                                                   
  **CYP3A5\*3**   ***n***   **%**    **MTHFR (C677T)**   ***n***   **%**    **UGT2B7\*2**    ***n***   **%**    **GSTM1**        ***n***   **%**    **GSTT1**        ***n***   **%**                               
                                                                                                                                                                                                                   
  \*1A/\*1A       17        6.72     CC                  36        20.00    \*1/\*1          68        26.88    null             161       63.64    null             160       88.88                               
  \*1A/\*3        86        33.99    CT                  100       55.56    \*1/\*2          170       67.19    null             92        36.36    null             20        11.11                               
  \*3/\*3         150       59,29    TT                  44        20.00    \*2/\*2          15        5.93     TOTAL            253       100.00   TOTAL            180       100.00                              
  TOTAL           253       100.00   TOTAL               180       24.44    TOTAL            253       100.00                                                                                                      
  *f*\*1A         0.24               fc                  0.48               *f*\*1           0.60                                                                                                                  
  *f*\*3          0.76               ft                  0.52               *f*\*2           0.40                                                                                                                  

###### 

**Comparison of allelic frequencies of CYP1A1, CYP1A2, CYP2A6, CYP3A4, CYP3A5, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, GSTM1, GSTT1, UGT2B7, and MTHFR in Caucasian, Japanese, and Chilean populations**.

                                                                                                        Alle Frequencies                 
  --------- ------ ----------------------------- -------------------------------- --------------------- ------------------ ------ ------ ------------------------------------------------------------------------------
  CYP1A1    \*2A   rs4646903                     T3801C                           Increased             0.37               0.36   0.09   Murata et al. ([@B54])
            \*2C   rs1048943                     A2454G (I462V)                   Decreased             0.32               0.22   0.05   Murata et al. ([@B54])
  CYP1A2    \*1F   rs762551                      C-163A                           Higher inducibility   0.77               0.68   0.61   Sachse et al. ([@B70]), Skarke et al. ([@B74]), Chida et al. ([@B17])
  CYP2A6    \*2    rs1801272                     T479A (L160H)                    None                  0.02               0.02   0.00   Nakajima et al. ([@B55]), Chen et al. ([@B15])
            \*3    rs56256500                    CYP2A6/CYP2A7 hybrid             Decreased?            0.00               0.00   0.00   
            \*4    rs3892097                     Deletion                         None                  0.04               0.00   0.19   
  CYP3A4    \*1B   rs2740574                     A-392G                           Decreased             0.06               0.04   0.00   Paris et al. ([@B58])
            \*17   rs4987161                     T15615C                          Decreased             0.00               0.00   0.00   
  CYP3A5    \*3    rs776746                      A6986G Splicing defect           Decreased             0.76               0.70   0.75   Kurose et al. ([@B43]), Roy et al. ([@B69])
  CYP2C8    \*3    rs10509681                    G2130A, A30411G (R139K, K399R)   Decreased             0.06               0.16   0.00   Agúndez et al. ([@B3])
  CYP2C9    \*2    rs1799853                     C3608T (R144C)                   Decreased             0.06               0.08   0.00   Agúndez et al. ([@B3]), Sullivan-Klose et al. ([@B76]), Nasu et al. ([@B56])
            \*3    rs1057910                     A42614C (I359L)                  Decreased             0.04               0.06   0.03   
  CYP2C19   \*2    rs28399504                    G19154A Splicing defect          None                  0.12               0.14   0.23   Kurose et al. ([@B43])
            \*3    rs4986893                     G17948A W212X                    None                  0.00               0.00   0.11   
  CYP2D6    \*2    rs16947                       C2850T (R296C)                   Normal                0.41               0.32   0.13   Kurose et al. ([@B43])
            \*3    rs35742686                    del2549A(259 Frame shift)        None                  0.01               0.02   0.00   
            \*4    rs3892097                     G1846A Splicing defect           None                  0.12               0.21   0.00   
  CYP2E1    \*5B   rs2031920/rs3813867           G-1293C/C-1053T                  Decreased             0.15               0.04   0.20   Krishnakumar et al. ([@B42])
            \*6    rs6413432                     T7632A                           Decreased             0.22               0.08   0.29   Krishnakumar et al. ([@B42])
  GSTM1     null   SNP500Cancer ID -- GSTM1-02   Null deletion                    None                  0.20               0.45   0.55   Kurose et al. ([@B43])
  GSTT1     null   SNP500Cancer ID -- GSTT1-02   Null Deletion                    None                  0.11               0.52   0.20   Kurose et al. ([@B43])
  UGT2B7    \*2    rs7439366                     C802T (H268Y)                    Decreased             0.40               0.49   0.27   Bhasker et al. ([@B10])
  MTHFR     T      rs1801133                     C677T (A222V)                    Thermolabile enzyme   0.52               0.41   0.32   Matsuo et al. ([@B52]), Chen et al. ([@B16])

Our results show the absence of variant alleles *CYP2A6*\**3*, *CYP2C19*\**3*, and *CYP3A4*\**17* such as it was also observed for Caucasians. In Japanese people *CYP2A6*\**3* and *CYP3A4*\**17* are also absent, but the *CYP2C19*\**3* allele has a frequency of 0.11. *CYP1A1*\**2A* and *CYP2A6*\**2* allele frequencies are similar to Caucasians but higher than the reported for Japanese people. *CYP3A5*\**3* and *CYP2C9*\**3* frequencies are similar to those in Japanese people, but different to the Caucasian people. *CYP1A1*\**2C*, *CYP1A2*\**1F*, *CYP3A4*\**1B*, and *CYP2D6*\**2* allelic frequencies are higher than those observed either in Caucasian or Japanese populations. *MTHFR*T allele frequency is higher than the observed in Caucasian and Japanese population, but also than the frequency reported previously by Nitsche et al. ([@B57]) in other group of the Chilean population. We suggest that this difference could be explained by different genetic composition of the previously studied group, which could be more similar to Caucasians. Unfortunately, Nitsche et al. no reported the Amerindian-Caucasian admixture percentage to evaluate this point.

On the other hand, *CYP2C19*\**2*, *GSTT1* null and *GSTM1* null frequencies are lower than those reported in Caucasian or Japanese population. Finally for *CYP2C8*\**3*, *CYP2C9*\**2* and \**3*, *CYP2D6*\**3*, *CYP2D6*\**4*, *CYP2E1*\**5B* and \**6*, as well as for *UGT2B7*\**2* the frequencies described for Chileans are intermediate in relation to those described for Caucasian and Japanese population (Sullivan-Klose et al., [@B76]; Nasu et al., [@B56]; Chen et al., [@B16], [@B15]; Chida et al., [@B17]; Paris et al., [@B58]; Sachse et al., [@B70]; Bhasker et al., [@B10]; Matsuo et al., [@B52]; Murata et al., [@B54]; Roy et al., [@B69]; Skarke et al., [@B74]; Nakajima et al., [@B55]; Krishnakumar et al., [@B42]; Kurose et al., [@B43]), which is expected because Chilean population is considered a mixed ethnicity between both races.

Some limitations in this study should be pointed out. Only some polymorphism of the many (\>80) CYP2D6 known were genotyped. We select only CYP2D6 polymorphisms that have shown better reported relationship with plasma levels of antineoplastic drugs and those that have higher allele frequencies, based on a previous pilot study in Chilean subjects (Dr. Monica Acuña, Personal Communication). Similarly, same criteria were used for choosing the other studied polymorphisms, based on both literature and our own previous research. Nevertheless, some potentially relevant CYP variants are currently under investigation in our laboratory (CYP2D6\*2xN, CYP2D6\*5, CYP2D6\*10, CYP2C8\*3, and CYP2C8\*4), to complement the results shown in this paper.

Additionally, we have no data for other relevant polymorphic enzymes, such as for example, CYP1B1 and CYP2B6, responsible for the metabolism of several antineoplastic drugs (Quiñones et al., [@B62]) and UDP Glucuronyl transferase 1A1, involved in metabolism of irinotecan (Dias et al., [@B23]). We did not analyze thiopurine *S*-methyltransferase (TPMT), a cytosolic phase II enzyme involved in the metabolism of azathioprine, thiopurine, and thioguanine (Zhou, [@B84]). However the frequency of four allelic variants of this gene (\*2, \*3A, \*3B, and \*3C) were analyzed previously in Chilean population by Alvarez et al. ([@B5]) showing that the presence of \*3A allele is the most prevalent, which is similar to Caucasians, giving a first approach to the use of this polymorphism in clinical practice in Chilean patients.

Another limitation of the present research is the use of Japanese population as proxy of the ancestral Asians of Chilean people. We use this population as reference due to two main facts: (a) there is very good and complete information about these polymorphisms in Japanese people and (b) recently, have been reported no great differences among Japanese and other Asian populations, particularly with respect to Chinese population (Kurose et al., [@B43]).

On the other hand, drug--drug pharmacological interactions, some epigenetic and environmental factors, and alternative metabolic routes should not be excluded to describe response to antineoplastic agents, which is *per se* a multifactorial event. Thus, the research in this area must identify these factors and potential gene -- environment interactions that modulate response to these drugs.

Some polymorphisms have been studied in other South American countries (Isaza et al., [@B37]; Gaspar et al., [@B30]; Fernández et al., [@B25]; Gattas et al., [@B31]; Vianna-Jorge et al., [@B78]; Almeida et al., [@B4]; Lizcano Fernández, [@B50]; Rossini et al., [@B68]; Schlawicke et al., [@B72]; Canalle et al., [@B12]; Rodríguez et al., [@B66]; Castaño-Molina et al., [@B13]; Dorado et al., [@B24]), but the comparison with Chilean Mestizo population is very difficult because of the divergent origin of these populations. Chilean population is different from other South American countries, from Brazilian people for example, which have African and Portuguese contribution with great pharmacogenomic diversity, or from Argentina and Uruguay populations, which are multiethnic countries, with Amerindian-European admixture, but mostly with Italians (Lizcano Fernández, [@B50]). In this respect, in South America, the region one of the most diverse genetic background in the world, four main components have contributed to the present-day population: Amerindians (pre-Columbian inhabitants); Iberians (conquerors) who dominated the continent until the nineteenth century, Africans (imported as slaves by the colonizers); and post-independence immigrants from overseas (mostly Italy and Germany but also from France, South Asia, and Japan). Therefore, we suggest that studies of these pharmacogenes in Chileans should be used to develop pharmacogenetic tools for this specific population, rather than extrapolating results obtained to other populations.

The frequencies observed in metabolic polymorphism studied in Chilean population were distinct from paternal races. These results contribute to better understanding of the basis of ethnic variation in drug metabolism and response (Agúndez, [@B2]; García-Martín et al., [@B28]; Yasuda et al., [@B83]), and suggest a complex genetic profile of this "mestizo" population, which should be considered in pharmacotherapy, especially for drugs with a narrow safety range, particularly in cancer chemotherapy (García-Martín, [@B26]; Quiñones et al., [@B62]). These established genotype frequencies may be used for studying the phenotype variation in further studies. Thus, it may be a good contribution for further studies on the clinical application of pharmacogenomics in Asian-Caucasian mixed races.

Conclusion
==========

Profound variation in polymorphisms of metabolizing enzymes have been described in diverse populations, including enzymes that take part in the metabolism of chemotherapeutics drugs (50). In this sense, our results agree with these observations when we compare the analyzed sub-group with Asian and Caucasian populations (Table [4](#T4){ref-type="table"}).

As Chilean population represents a mixed ethnicity mainly between native-Americans and Caucasians (mostly Spaniards) the data obtained might help to understand inter ethnic differences not only for single polymorphisms, but also the function of simultaneous polymorphisms in metabolic genes in each subject, to explain differences in response to chemotherapy.

This investigation contributes to have a first pattern of several relevant polymorphisms in metabolizing enzymes (*CYP1A1*, *CYP1A2*, *CYP2A6*, *CYP2C8*, *CYP2C9*, *CYP2C19*, *CYP2D6*, *CYP2E1*, *CYP3A4/5*, *GSTM1*, *GSTT1*, *UGT2B7*, *and MTHFR*) in Chilean people, which can give course for a genetic -- population investigation of these polymorphisms helping to the understanding of susceptibility to drugs and pathologies in this population, which already has been suggested by our group of research for some specific genes (Quiñones et al., [@B60], [@B61], [@B62]; Acevedo et al., [@B1]; Lee et al., [@B45]; Cordero et al., [@B21]).

The knowledge of genetic variants involved in the metabolism of the antineoplastic drugs in the Chilean population will help to the prediction of their clinical efficacy and/or toxicity, and therefore, will help us to the design personalized cancer treatments to improve therapeutic response and diminish the adverse effects improving cost-efficacy of treatments.

Finally, based on scientific literature and our experience, we believe that, at least in Chilean population, MTHFR/methotrexate, GST/cisplatin, and CYP2D6/tamoxifen are the potential more relevant gene/drug pairs which are closer for monitoring use in clinical practice.
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